[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer-stage-iii\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer-stage-iii":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,67,97,121,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100559428","phase-2-neoadjuvant-umbrella-trial-for-patients-with-unresectable-stage-iii-nsclc-harboring-rare-mutations-100559428",false,"NCT06563999","Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.","Neoadjuvant Umbrella Trial Directed by Next Generation Sequencing for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations (Without EGFR Sensitizing Mutations)","NUMER","Inclusion Criteria:\n\n* Subjects must have treatment-naive unresectable stage III NSCLC according to the AJCC 8th edition staging;\n* Squamous or non-squamous NSCLC histology;\n* Subjects should have a rare mutation based on NGS, including mutations of EGFR exon20ins, ROS1 fusion, RET fusion, NTRK fusion, MET 14 exon, HER2, BRAF V600E, KRAS G12C, and ALK fusion.\n* Subjects should be without EGFR exon 19 deletions or exon 21 L858R activating mutation;\n* Male and female, aged 18-75 years;\n* Blood and specimens before and after treatment must be provided;\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n* Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109\u002FL, and Platelet count ≥100 x 109\u002FL, and Hemoglobin ≥9 g\u002FdL (may be transfused to maintain or exceed this level);\n* Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN;\n* Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml\u002Fmin;\n* Female subjects should not be pregnant or breast-feeding;\n* Written informed consent provided. Being willing and able to comply with the visits, treatment plan, laboratory examinations and other study procedures scheduled in the study.\n\nExclusion Criteria:\n\n* Not unresectable stage III disease according to the investigator;\n* Subjects with known EGFR sensitive mutations;\n* Previous treatment with systemic antitumor therapy for NSCLC;\n* Eye inflammation or eye infection not fully treated or conditions predisposing the subject to this.\n* History of another malignancy in the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted.\n* Evidence of clinically active interstitial lung disease;\n* Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);\n* Inability to comply with protocol or study procedures;\n* Any unstable systemic disease (including active infection, active tuberculosis uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease);\n* A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study and may confuse the study results;\n* Women who are pregnant or nursing.\n* Ingredients mixed with small cell lung cancer patients.","ALL","18 Years","75 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This umbrella trial directed by next generation sequencing (NGS) includes patients with treatment-naive unresectable stage III non-small-cell lung cancer (NSCLC). The aim of the umbrella study is to evaluate the efficacy of induction NGS-directed targeted therapies followed by surgery for stage III NSCLC patients whose tumor harbors a rare mutation.",[28,29],"Lung Cancer Stage III","Mutation",[31,32,33,34],"stage III NSCLC","rare mutations","umbrella trial","neoadjuvant","RECRUITING","2026-04-19",{"date":38,"type":39},"2026-04-21","ACTUAL",{"date":41,"type":39},"2024-11-01",{"date":43,"type":22},"2029-11-01",{"name":45,"class":46},"Sun Yat-sen University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":47},"100352730","phase-2-neoadjuvant-ibi308-bevacizumab-plus-pemetrexed-and-carboplatin-followed-by-surgery-in-unresectable-stage-iii-nsclc-100352730","NCT03872661","Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC","A Multicenter Phase II Trial of Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","NIBCUN","Inclusion Criteria:\n\n* Target population is unresectable stage III non-small cell lung cancer.\n* Written informed consent provided.\n* Subjects should not have a previously detected sensitizing EGFR mutation or ALK fusion oncogene.\n* Male and female patients aged ≥18 years, \\\u003C 75 years.\n* Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Life expectancy ≥12 weeks.\n* Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109\u002FL, and Platelet count ≥100 x 109\u002FL, and Hemoglobin ≥9 g\u002FdL (may be transfused to maintain or exceed this level).\n* Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN in subjects without liver metastases; ≤ 5 x ULN in subjects with liver metastases.\n* Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml\u002Fmin.\n* Female subjects should not be pregnant or breast-feeding.\n\nExclusion Criteria:\n\n* Known severe hypersensitivity to IBI308 or any of the excipients of this product.\n* Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody (including any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).\n* Prior chemotherapy or radiotherapy.\n* Subjects with active, known or suspected autoimmune disease. Subjects in conditions not expected to recur in the absence of an external trigger, or not requiring systemic treatment are permitted to enroll.\n* Subjects with a condition requiring systemic treatment with either corticosteroids (\\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n* Inability to comply with protocol or study procedures.\n* A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.\n* A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease.\n* History of another malignancy in the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted.\n* Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).\n* Patient who has active serious infection (e.g. pyrexia of or 38.0℃ over)\n* Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).\n* Known history of active Hepatitis B or C.\n* Women who are pregnant or nursing.\n* Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicated the use of an investigational drug or puts the subject at high risk for treatment-related complications.",{"count":57,"type":22},36,[25],"The purpose of this study is to studying neoadjuvant IBI308, bevacizumab, plus pemetrexed and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III non-small cell lung cancer.",[28],{"date":38,"type":39},{"date":63,"type":39},"2019-03-01",{"date":65,"type":22},"2029-12-31",{"name":45,"class":46},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100438572","phase-2-adding-certolizumab-to-chemotherapy--nivolumab-in-people-who-have-lung-cancer-that-can-be-treated-with-surgery-100438572","NCT04991025","Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery","Phase 2 Trial of Neoadjuvant Nivolumab + Platinum-based Chemotherapy + Certolizumab in Patients With Resectable Stages II-III Lung Cancers","Inclusion Criteria:\n\n* Untreated stage II-III (AJCC 8th edition) non-small cell lung cancers with operable and resectable disease determined by a thoracic surgeon\n* Histologic confirmation of disease at MSKCC\n* Age 18 years or older\n* Karnofsky Performance Status ≥ 70\n* Adequate bone marrow, liver and renal function, as specified below:\n\n  * Absolute Neutrophil Count (ANC) ≥ 1.5 x 10\\^9 \u002FL\n  * Lymphocyte count ≥0.5 x10\\^9\u002FL (500\u002FµL)\n  * Hemoglobin ≥ 9 g\u002FdL\n  * Platelets ≥ 100 x 10\\^9 \u002FL\n  * Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except for patients with documented Gilbert's Syndrome)\n  * AST and ALT ≤ 2.5 x ULN\n  * Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml\u002Fmin for patients with creatinine levels above institutional normal.\n  * Serum albumin ≥25 g\u002FL (2.5 g\u002FdL)\n  * For patients not receiving therapeutic anticoagulation: INR or aPTT ≤1.5 x ULN\n  * For patients receiving therapeutic anticoagulation: stable anticoagulant regimen\n* Negative PPD test or interferon-gamma release assay (including but not limited to QuantiFERON-TB Gold)\n* For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment\n* Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 5 months thereafter\n* Presence of at least one site of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors 1.1\n* Ability to provide written, informed consent. Legally Authorized Representatives are permitted.\n* Negative HIV test at screening, with the following exception: patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a CD4 count ³ 200\u002FµL, and have an undetectable viral load\n* Negative hepatitis B surface antigen (HBsAg) test at screening Negative total hepatitis B core antibody (HBcAb) test at screening, or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening. Note: The HBV DNA test will be performed only for patients who have a negative HBsAg test and a positive total HBcAb test.\n* Patient with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n\nExclusion Criteria:\n\n* Presence of an FDA approved targeted therapy for patients with NSCLC harboring a genomic aberration for which an FDA-approved targeted therapy is indicated\n* Hypersensitivity to platinum agents\n* Prior use of TNF-α inhibitor\n* Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment\n\nNote: this exclusion criteria has the following excpetions:\n\n* Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Principal Investigator confirmation has been obtained.\n* Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.\n* Topical steroids\n\n  * Active or history of autoimmune disease or immune deficiency\n  * Active or history of autoimmune disease or immune deficiency including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, psoriatic arthritis, antiphospholipid antibody syndrome Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, or multiple sclerosis.\n\nNote: This exclusion criteria has the following exceptions:\n\n1. Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.\n2. Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.\n3. Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:\n\n   * Rash must cover \\\u003C 10% of body surface area\n   * Disease is well controlled at baseline and requires only low-potency topical corticosteroids\n   * No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months\n\n     * History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan Note: History of radiation pneumonitis in the radiation field (fibrosis) is permitted\n     * Baseline hearing deficit (CTCAE version 4.0 grade 2 or higher)\n     * Ongoing bacterial, viral, or antifungal infection requiring antimicrobial treatment with the exception of thrush\n     * Active tuberculosis or untreated, latent tuberculosis Note: If a patient has signs, symptoms, or a history suggestive of active tuberculosis, evaluation by an infectious disease physician will be required and active tuberculosis ruled-out prior to enrollment.\n     * Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, or cerebrovascular accident) within 3 months prior to initiation of study treatment, or unstable arrhythmia Note: Patients are ineligible if they have a history of myocardial infarction or\n     * Unstable angina within the past 12 months\n     * Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study\n     * Acute or chronic Hepatitis B or C infection\n     * Known HIV infection requiring antiretroviral medications and those with AIDS\n     * Active herpes zoster infection\n     * Current treatment with anti-viral therapy for HBV\n     * Non-healed infected skin ulcers\n     * Uncontrolled or symptomatic hypercalcemia (ionized calcium \\> 1.5mmol\u002FL, calcium \\> 12mg\u002FdL or corrected serum calcium \\> ULN)\n     * Prior history of other malignancy with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\> 90%), such as adequately treated carcinoma in situ of the cervix, non melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, Stage I uterine cancer, localized prostate cancer, non-melanomatous skin cancer, ductal carcinoma or lobular carcinoma in situ of the breast\n     * Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia\n     * Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment Note: Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.\n     * Prior allogeneic stem cell or solid organ transplantation\n     * Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications\n     * Live, attenuated vaccines (e.g., FluMist) are prohibited within 4 weeks prior to initiation of study treatment, during treatment with nivolumab, and for 5 months after the last dose of nivolumab.\n     * Treatment with investigational therapy within 28 days prior to initiation of study treatment\n     * Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies\n     * Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 \\[IL-2\\]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment\n     * History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins\n     * Known hypersensitivity to Chinese hamster ovary cell products or to any component of the nivolumab formulation\n     * Known allergy or hypersensitivity to any component of the Certolizumab pegol formulation\n     * Known allergy or hypersensitivity to any component of the platinum-based chemotherapy formulations\n     * Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of nivolumab, within 3 months after the final dose of Certolizumab pegol, and within 6 months after the final dose of carboplatin, cisplatin, pemetrexed or gemcitabine treatment",{"count":75,"type":22},60,[25],"The purpose of the study is to explore adding the study drug certolizumab to standard chemotherapy as it may reduce the inflammation caused by the cancer and make the chemotherapy more effective in shrinking the cancer. This study will examine whether adding certolizumab to the usual treatment approach is better than, the same as, or worse than the usual approach alone.",[79,80,28],"Lung Cancer","Lung Cancer Stage II",[82,83,84,85,86,87],"Untreated Lung Cancer","resectable lung cancer","operable lung cancer","Certolizumab","Memorial Sloan Kettering Cancer Center","21-152","2025-10-16",{"date":90,"type":39},"2025-10-20",{"date":92,"type":39},"2022-10-19",{"date":94,"type":22},"2026-10",{"name":86,"class":46},7,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":47},"100590500","phase-3-bovine-reinforcement-in-stomach-colorectal-and-lung-operation-100590500","NCT06968221","Bovine Reinforcement in Stomach, Colorectal and Lung Operation","A Study on the Safety and Efficacy of Using Cingular Bovine Pericardium Anastomosis Reinforcement Membrane for Tissue Reinforcement and Hemostasis at Anastomotic Sites","Inclusion Criteria:\n\n* Subjects who will undergo operation with stapled stomach, colorectal anastomosis with or without reinforcement\n* Subjects willing to accept informed consent and willing to attend the follow up\n\nExclusion Criteria:\n\n* Subjects who have significant intraoperative hypotension or cardiac events.\n* Subjects with collagen vascular disease, coagulopathy, significant renal or hepatic dysfunction (creatinine \\>1.6 or liver enzymes \\> 50% upper limit of normal values).\n* Subjects have uncontrolled intra-abdominal infection",{"count":105,"type":22},172,[107],"PHASE3","The primary purpose of this prospective, randomized multicenter center study is to evaluate and compare the outcomes of stomach,colorectal and lung anastomoses reinforced with a bioabsorbable staple line reinforcement material compared with standard non-reinforced techniques with respect to the incidence of postoperative hemorrage rate, anastomotic leakage, if applicable.",[110,28],"Rectal Cancer Stage III","2025-05-12",{"date":113,"type":39},"2025-05-15",{"date":115,"type":39},"2025-05-01",{"date":117,"type":22},"2026-10-31",{"name":119,"class":120},"Shanghai Cingularbio Co. Ltd","INDUSTRY",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":131,"studyType":132,"phases":4,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":5},"100524674","clinical-validation-and-benchmarking-of-top-performing-ctdna-diagnostics---stage-iii-nsclc-100524674","NCT06111807","Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC","GUIding Multi-moDal thErapies Against MRD by LiquidBiopsies in Non Small Cell Lung Cancer- GUIDE.MRD-03-NSCLC","MRD-LUNG","Inclusion Criteria:\n\n* NSCLC, clinical tumor stage III (cT1-4, cN0-3, M0).\n* Patient 18 years or older.\n* Scheduled for curative intent treatment (surgery and\u002For radiotherapy).\n* Patient able to understand and sign written informed consent.\n* Baseline contrast enhanced CT thorax abdomen (or PET\u002FCT), MRI (or CT) brain, Pulmonary function tests (at least FEV1 and DLCO\u002FKCO).\n* Ability to obtain sufficient tumor material (≥50ng tumor DNA, FFPE ). Either at baseline or after surgery.\n\nExclusion Criteria:\n\n* Verified distant metastases.\n* With synchronous NSCLC cancer and non-NSCLC cancer (except skin cancer other than melanoma).\n* With other cancers (excluding NSCLC or skin cancer other than melanoma, or cancers treated curatively with follow up of more than 5 years without recurrence).\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study.\n* No tissue sample available for the project, or tumor content in the tissue sample is \\\u003C20%",{"count":130,"type":22},248,"3 Years","OBSERVATIONAL","Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for non small cell lung cancer (NSCLC), the methods used to decide who gets additional post radical (surgery or definite chemo-radiotherapy) treatment are suboptimal. Some patients get too much treatment, while others do not get enough.\n\nThere is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.\n\nThe GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.\n\nGUIDE.MRD-03-NSCLC is a part of the GUIDE.MRD project.",[28],[136,137,138,139,140,141],"Circulating tumor DNA","ctDNA diagnostics","Minimal residual disease","Sensitivity","Specificity","complete pathological response","2025-03-25",{"date":144,"type":39},"2025-03-30",{"date":146,"type":39},"2023-11-10",{"date":148,"type":22},"2030-07-31",{"name":150,"class":46},"University Medical Center Groningen",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":161,"studyType":132,"phases":4,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":173,"locationsCount":47},"100459117","cor-loco-regional-advanced-lung-cancer-treated-with-chemo-radiotherapy-cola-100459117","NCT05258448","COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)","The Effect of Radiotherapy on the Heart in Loco-regional Advanced NSCLC Patients Treated With Definitive Radiotherapy Measured by Cardiac MR","COLA","Inclusion Criteria:\n\n* Age ≥ 18 Years\n* Inoperable and histologically\u002Fcytologically verified NSCLC.\n* Planned treatment with curative intent.\n* Capable of completing study procedures ECG and Cardiac MR.\n* Able of giving written and informed consent before study procedures are initiated.\n\nExclusion Criteria:\n\n* Vulnerable patients.\n* Patients with operable devices as pacemaker\u002FICD and cochlear implant or other conditions where MR scan is contraindicated.\n* Claustrophobia.",{"count":160,"type":22},100,"2 Years","Patients with loco-regional NSCLC planned for curative treatment with chemoradiotherapy will be invited to participate in a prospective study; besides routine treatment, the patients will be followed with an ECG and cardiac MR for at least two years after radiotherapy treatment.",[164,28,80,165,166],"Cardiac Toxicity","Radiation Toxicity","Cardiac Disease","2023-12-05",{"date":169,"type":39},"2023-12-06",{"date":171,"type":39},"2015-08",{"date":94,"type":22},{"name":174,"class":46},"Odense University Hospital"]